Quick 5 min look at their results:
- Targeted adults (Neuren was 5-15 years old)
- Smaller sample size (25 patients vs Neuren's 82)
- Much smaller dose (5mg daily vs up to 200mg/kg for Neuren's trial)
- More statistically significant results in CGI(P values of 0.014 vs Neuren's 0.029)
- Similar statistically significant results in RSBQ (0.048 vs Neuren's 0.042)
Looks good for Anavex.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$14.43 |
Change
-0.140(0.96%) |
Mkt cap ! $1.798B | |||
| Open | High | Low | Value | Volume |
| $14.50 | $14.56 | $14.16 | $1.880M | 131.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 56 | $14.41 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.43 | 44 | 3 |
View Market Depth
| Last trade - 14.05pm 14/07/2025 (20 minute delay) ? |
| NEU (ASX) Chart |